| Mar 1 2024 |
FDA Finalizes Revised Medical Device Quality System Requirements, Issues Remote Regulatory Assessments Guidance |
McDermott Will & Schulte LLP |
| Mar 1 2024 |
FDA Announces Qualified Health Claim for Yogurt and Reduced Risk of Type 2 Diabetes |
Keller and Heckman LLP |
| Feb 29 2024 |
Innovation in Biotech and AI (VIDEO) |
Foley & Lardner LLP |
| Feb 29 2024 |
Petition Filed to Add Iso-butanol to List of Chemical Substances Subject to Superfund Excise Tax |
Bergeson & Campbell, P.C. |
| Feb 29 2024 |
FDA Issues Guidance for Industry on Foods Derived from Plants Produced Using Genome Editing |
Bergeson & Campbell, P.C. |
| Feb 29 2024 |
New York City's Health Care Price Transparency Law Takes Effect |
Mintz |
| Feb 29 2024 |
Weekly IRS Roundup February 19 – February 23, 2024 |
McDermott Will & Schulte LLP |
| Feb 29 2024 |
District Court Elucidates the Meaning of “to Induce” Under the Federal Health Care Program Anti-Kickback Statute |
Sheppard, Mullin, Richter & Hampton LLP |
| Feb 29 2024 |
Navigating the Regulatory Maze: Understanding the ASA Ruling re. Supreme CBD |
Squire Patton Boggs (US) LLP |
| Feb 28 2024 |
Federal Court Ruling Suspends Compliance with Certain Reporting Obligations Under Oregon Drug Price Transparency Program |
ArentFox Schiff LLP |
| Feb 28 2024 |
Library of Congress Publishes Article on South Korea’s Act on Promoting the Green Bio Industry |
Bergeson & Campbell, P.C. |
| Feb 28 2024 |
Senator Sanders Calls for Robust Front of Pack Labeling Requirements |
Keller and Heckman LLP |
| Feb 28 2024 |
Understanding the Risks Associated with Social Media Marketing |
Foley & Lardner LLP |
| Feb 27 2024 |
CMS Releases Part Two of Guidance for the Inflation Reduction Act’s Medicare Prescription Payment Plan |
Mintz |
| Feb 27 2024 |
FDA 2023-24: A Look Back & A Peek Forward |
Polsinelli PC |
| Feb 27 2024 |
Family Dollar Pleads Guilty to Food and Drug Adulteration Charge |
Keller and Heckman LLP |
| Feb 27 2024 |
FDA Releases Updated Directory on Select Dietary Supplement Ingredients |
Epstein Becker & Green, P.C. |
| Feb 27 2024 |
This Week in 340B: February 21 – 26, 2024 |
McDermott Will & Schulte LLP |
| Feb 27 2024 |
This Week in 340B: February 14 – 20, 2024 |
McDermott Will & Schulte LLP |
| Feb 26 2024 |
2023 Health Care Employment Law Year in Review |
K&L Gates LLP |
| Feb 26 2024 |
Court Finds Access to Botox Trade Secrets and Similarity of Competitor Product Supported Inference of Trade Secrets Misappropriation |
Proskauer Rose LLP |
| Feb 26 2024 |
ISTAND Pilot Program Accepts First AI-Based Digital Health Technology |
Greenberg Traurig, LLP |
| Feb 26 2024 |
Mallinckrodt Trust Asserts Novel Argument in Response to Safe Harbor Defense (US) |
Squire Patton Boggs (US) LLP |
| Feb 23 2024 |
High Stakes: New Proposed Philadelphia Ordinance Regulating Skill-Based Games at Odds with State Police Cases |
Norris McLaughlin P.A. |
| Feb 23 2024 |
ECHA Begins Public Consultation on Recommending Authorization for Five SVHCs and Adding a New Hazard to DBP |
Bergeson & Campbell, P.C. |
| Feb 23 2024 |
EPA and DOE Announce Funding to Spur Development of Advanced Biofuels |
Bergeson & Campbell, P.C. |
| Feb 23 2024 |
FDA Issues Guidance on Voluntary Premarket Engagement for Foods Derived from Plants Produced Using Genome Editing |
Keller and Heckman LLP |
| Feb 22 2024 |
Mixed Beverage Definition Gaining Traction in Indiana |
McDermott Will & Schulte LLP |
| Feb 22 2024 |
Mintz IRA Update — Legal Challenges to the Medicare Drug Price Negotiation Program Continue |
Mintz |
| Feb 22 2024 |
Mintz IRA Update — The IRA in 2024: The Medicare Drug Price Negotiation Program in Full Swing and Other Developments |
Mintz |
| Feb 22 2024 |
A Guide for FDA Whistleblowers |
Oberheiden P.C. |
| Feb 22 2024 |
Regulatory Certainty for Biosimilars in Mexico |
OLIVARES |
| Feb 22 2024 |
Top Legal Considerations for the GCs and CFOs in the Life Sciences Industry in 2024 |
ArentFox Schiff LLP |
| Feb 21 2024 |
FDA Launches New Directory of Ingredients Used in Dietary Supplements |
Keller and Heckman LLP |
| Feb 21 2024 |
NNI Webinar on Nanometrology for Nanoscale Medical and Pharmaceutical Products Will Be Held March 1, 2024 |
Bergeson & Campbell, P.C. |
